Literature DB >> 33482765

Raptor and rictor expression in patients with human papillomavirus-related oropharyngeal squamous cell carcinoma.

Shunsuke Kondo1, Hitoshi Hirakawa1, Taro Ikegami1, Takayuki Uehara1, Shinya Agena1, Jin Uezato1, Hidetoshi Kinjyo1, Noritomo Kise1, Yukashi Yamashita1, Katsunori Tanaka1, Narumi Hasegawa2, Asanori Kiyuna1, Hiroyuki Maeda1, Mikio Suzuki3, Akira Gahana1,4.   

Abstract

BACKGROUND: Despite reports of a link between human papillomavirus (HPV) infection and mechanistic target of rapamycin (mTOR) signaling activation, the role of the mTOR pathway, especially raptor and rictor, in HPV-related head and neck cancer is still unclear. The aim of the present study was to elucidate the role of the mTOR pathway in HPV-related oropharyngeal squamous cell carcinoma (OPSCC).
METHODS: The present study involved two strategies. The first was to investigate the activity of mTOR and mTOR-related complexes in high-risk HPV-positive (UM-SCC47 and CaSki) and HPV-negative (SCC-4 and SAS) cancer cell lines. The second was to elucidate mTOR complex expression in 80 oropharyngeal cancer tissues and to examine the relationship between mTOR complex expression and survival in patients with OPSCC.
RESULTS: The UM-SCC47 and CaSki cell lines showed high gene and protein expression of raptor. They also exhibited G1/S and G2/M phase cell cycle arrest following 24 h incubation with 6 μM temsirolimus, a rapamycin analog, and temsirolimus administration inhibited their growth. HPV-related OPSCC samples showed high gene and protein expression of raptor and rictor compared with HPV-unrelated OPSCC. In addition, HPV-related OPSCC patients with high raptor and rictor expression tended to have a worse prognosis than those with low or medium expression.
CONCLUSIONS: These results suggest that raptor and rictor have important roles in HPV-related OPSCC and that temsirolimus is a potential therapeutic agent for patients with HPV-related OPSCC. This is the first report to reveal the overexpression of raptor and rictor in HPV-related OPSCC.

Entities:  

Keywords:  Human papillomavirus; Oropharyngeal cancer; Overall survival; Rapalog; Raptor; Rictor; Temsirolimus; mTOR

Mesh:

Substances:

Year:  2021        PMID: 33482765      PMCID: PMC7821513          DOI: 10.1186/s12885-021-07794-9

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  51 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

2.  Personalized Medicine and the Contradictions and Limits of First-Generation Deescalation Trials in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer.

Authors:  Ester Orlandi; Lisa Licitra
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-02-01       Impact factor: 6.223

3.  Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma.

Authors:  Zeyi Deng; Masahiro Hasegawa; Yukashi Yamashita; Sen Matayoshi; Asanori Kiyuna; Shinya Agena; Takayuki Uehara; Hiroyuki Maeda; Mikio Suzuki
Journal:  Cancer Sci       Date:  2012-10-17       Impact factor: 6.716

4.  De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.

Authors:  Liam Masterson; Daniel Moualed; Zi Wei Liu; James E F Howard; Raghav C Dwivedi; James R Tysome; Richard Benson; Jane C Sterling; Holger Sudhoff; Piyush Jani; Peter K C Goon
Journal:  Eur J Cancer       Date:  2014-08-01       Impact factor: 9.162

5.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

6.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321

7.  mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor.

Authors:  Janine Masri; Andrew Bernath; Jheralyn Martin; Oak D Jo; Raffi Vartanian; Alexander Funk; Joseph Gera
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

8.  TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).

Authors:  V Grünwald; U Keilholz; A Boehm; O Guntinas-Lichius; B Hennemann; H J Schmoll; P Ivanyi; M Abbas; U Lehmann; A Koch; A Karch; A Zörner; T C Gauler
Journal:  Ann Oncol       Date:  2014-12-19       Impact factor: 32.976

9.  GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.

Authors:  Junghui Koo; Xuerong Wang; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Shi-Yong Sun
Journal:  Oncotarget       Date:  2015-04-20

10.  Detection of human papillomavirus in branchial cleft cysts.

Authors:  Taro Ikegami; Takayuki Uehara; Zeyi Deng; Shunsuke Kondo; Hiroyuki Maeda; Asanori Kiyuna; Shinya Agena; Hitoshi Hirakawa; Yukashi Yamashita; Akira Ganaha; Mikio Suzuki
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

View more
  6 in total

Review 1.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

Review 2.  The Translational Regulation in mTOR Pathway.

Authors:  Miaomiao Yang; Yanming Lu; Weilan Piao; Hua Jin
Journal:  Biomolecules       Date:  2022-06-08

Review 3.  Crosstalk between autophagy inhibitors and endosome-related secretory pathways: a challenge for autophagy-based treatment of solid cancers.

Authors:  Martina Raudenska; Jan Balvan; Michal Masarik
Journal:  Mol Cancer       Date:  2021-10-27       Impact factor: 27.401

4.  Prospects and hot spots for mammalian target of rapamycin in the field of neuroscience from 2002 to 2021.

Authors:  Lijun Li; Xiaojing Xia; Yunfeng Luo; Yuanting Zhu; Xuhong Luo; Baolin Yang; Lei Shang
Journal:  Front Integr Neurosci       Date:  2022-09-01

Review 5.  Autophagy Modulators in Cancer Therapy.

Authors:  Kamila Buzun; Agnieszka Gornowicz; Roman Lesyk; Krzysztof Bielawski; Anna Bielawska
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

6.  Prognostic association of starvation-induced gene expression in head and neck cancer.

Authors:  Masakazu Hamada; Hiroaki Inaba; Kyoko Nishiyama; Sho Yoshida; Yoshiaki Yura; Michiyo Matsumoto-Nakano; Narikazu Uzawa
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.